Antitumor studies. Part 1: Design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 1, 2007, Pages 242-256

  Ali, Hamed I ^a   Tomita, Keiichiro ^a   Akaho, Eiichi ^b   Kambara, Hiroto ^b   Miura, Shinji ^c   Hayakawa, Hiroyuki ^c   Ashida, Noriyuki ^c   Kawashima, Yutaka ^d   Yamagishi, Takehiro ^d   Ikeya, Hisao ^d   Yoneda, Fumio ^e   Nagamatsu, Tomohisa ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b High Technology Research Center (Life Science Center)   (Japan)

^c YAMASA CORPORATION   (Japan)

^d TAISHO PHARMACEUTICAL CO LTD   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Antitumor activity; AutoDock; Flavin analog; Protein tyrosine kinase

Indexed keywords

10 ETHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 10 ETHYL 4,10 DIHYDRO 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 10 ETHYL 4,10 DIHYDRO 7 METHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 10 ETHYL 7 METHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 10 METHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 4,10 DIHYDRO 10 ISOPROPYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 10 METHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 6,7,8 TRIMETHOXY 10 METHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 7 METHOXY 10 METHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 7,10 DIMETHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 8 METHOXY 10 METHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 4,10 DIHYDRO 9,10 DIMETHYL 4 OXO 2 PHENYLBENZO[G]PTERIDINE 5 OXIDE; 7 METHOXY 10 METHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 7,10 DIMETHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 8 METHOXY 10 METHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 8 METHOXY 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 9 METHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; 9,10 DIMETHYL 2 PHENYLPYRIMIDO[4,5 B]QUINOLIN 4(10H) ONE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DOXORUBICIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUDE MOUSE; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXIDES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

MUS MUSCULUS;

EID: 33750945838     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.09.063     Document Type: Article

References (24)

1. O'Brien D.E., Weinstock L.T., and Cheng C.C. J. Heterocycl. Chem. 7 (1970) 99
2. Hemmerich P., Massey V., and Fenner H. FEBS Lett. 84 (1972) 5
3. Graham D.W., Brown J.E., Ashton W.T., Brown R.D., and Rogers E.F. Experientia 33 (1977) 1274
4. Nagamatsu, T.; Yoneda, F.; Kawashima,Y.; Yamagishi, T.; Ikeya, H. The 6th Annual meeting of Division of medicinal chemistry, 1987, Tsukuba, Japan, Book Abstract, pp.148.
5. Kanaoka Y., Ikeuchi Y., Kawamoto T., Bessho K., Akimoto N., Mikata Y., Nishida M., Yano S., Sasaki T., and Yoneda F. Bioorg. Med. Chem. 6 (1998) 301
6. Kimachi T., Yoneda F., and Sasaki T. J. Heterocycl. Chem. 29 (1992) 763
7. Kawamoto T., Ikeuchi Y., Hiraki J., Eikyu Y., Shimizu K., Tomishima M., Bessho K., Yoneda F., Mikata Y., Nishida M., and Ikehara K. Bioorg. Med. Chem. Lett. 5 (1995) 2115
8. Lewis R.A. J. Med. Chem. 48 (2005) 1638
9. Ooms F. Curr. Med. Chem. 7 (2000) 141
10. Anderson A.C. Chem. Biol. 10 (2003) 787
11. Jackson R.C. Curr. Opin. Biotechnol. 6 (1995) 646
12. Hu, Z.; Wang, S.; Southerland, W.M. Dock odysseys II. ACS division of chemical information final program, The 228th ACS national meeting, August 22-26, 2004, Philadelphia, PA.
13. Yoneda F., Mori K., Ono M., Kadokawa Y., Nagao E., and Yamaguchi H. Chem. Pharm. Bull. 28 (1980) 3514
14. Coppola G.M., and Schuster H.F. J. Heterocycl. Chem. 26 (1989) 957
15. Goldner H., Dietz G., and Carstens E. Ann. 694 (1966) 142
16. Yoneda F., Sakuma Y., Mizumoto S., and Ito R. J. Chem. Soc. Perkin Trans. 1 1 (1976) 1805
17. Akinaga S., Gomi K., Morimoto M., Tamaoki T., and Okabe M. J. Biol. Chem. 265 (1991) 3632
18. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
19. Akaho E., Fujikawa C., Runion H.I., Hill C.R., and Nakaho H. J. Chem. Software 5 (1999) 147
20. Mosmann T. J. Immunol. Methods 65 (1983) 55
21. Miura S., Yoshimura Y., Endo M., Machida H., Matsuda A., Tanaka M., and Sasaki T. Cancer Lett. 129 (1998) 103
22. Inaba M., Tashiro T., Kobayashi T., Fujimoto S., Sakurai Y., Maruo K., Ohnishi Y., Ueyama Y., and Nomura T. Jpn. J. Cancer Res. 77 (1986) 190
23. Plummer M.S., Holland D.R., Shahripour A., Lunney E.A., Fergus J.H., Marks J.S., McConnell P., Mueller W.T., and Sawyer T.K. J. Med. Chem. 40 (1997) 3719
24. Murray-Rust P., and Glusker J.P. J. Am. Chem. Soc. 106 (1984) 1018